Anondita Medicare Ltd · ANONDITA · Contraceptives/Protectives · price as of the 18 November 2026 close, updated every trading day · results updated weekly · research updated 16 November 2026
Anondita Medicare share price today: ₹1,059.30 at the close on 18 November 2026, up 70.4% in a year. Anondita Medicare (ANONDITA) is worth ₹2,017 crore, trades at a P/E of 60.3 and has closed between ₹606.43 and ₹1,233.15 over the past 52 weeks.
Anondita Medicare Ltd's multiple is near its low because earnings grew even faster than a big multi-year rise in the share price. The multiple is low because of growth, not neglect. Results are still improving, and its P/E is higher than only 35% of its own 1-year history.
The main question: profits are rising, but only 8% of the last 2 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch.
The price has been rising for 58 weeks, and the P/E is lower than 65% of its own last 1 year. Over the last four quarters, results have been improving, with profit +110.0% on a year earlier, and 8% of the last 2 years' profit came in as cash. What will decide it: whether the cash starts to follow the profit.
What is the Anondita Medicare share price today?
Anondita Medicare Ltd's share price was ₹1,059.30 at the close on 18 November 2026. It has been rising for 58 weeks. That is 11.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹606 and ₹1,233, and at that close it sat 72% of the way up from that low.
A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Anondita Medicare Ltd is in stage 2. The phase helps read everything below.
Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 1 week running.
Week by week since 2025: did it beat the NIFTY 500 over the past 13 weeks?
Ahead in 38 of 55 weeks
| Week | 13-week return vs NIFTY 500 |
|---|---|
| 5 Sep 2025 | no NIFTY 500 reading |
| 12 Sep 2025 | no NIFTY 500 reading |
| 19 Sep 2025 | no NIFTY 500 reading |
| 26 Sep 2025 | no NIFTY 500 reading |
| 3 Oct 2025 | no NIFTY 500 reading |
| 10 Oct 2025 | no NIFTY 500 reading |
| 17 Oct 2025 | no NIFTY 500 reading |
| 24 Oct 2025 | no NIFTY 500 reading |
| 31 Oct 2025 | no NIFTY 500 reading |
| 7 Nov 2025 | no NIFTY 500 reading |
| 14 Nov 2025 | no NIFTY 500 reading |
| 21 Nov 2025 | no NIFTY 500 reading |
| 28 Nov 2025 | no NIFTY 500 reading |
| 5 Dec 2025 | +104.8% |
| 12 Dec 2025 | +97.9% |
| 19 Dec 2025 | +112.5% |
| 26 Dec 2025 | +161.4% |
| 2 Jan 2026 | +155.9% |
| 9 Jan 2026 | +119.5% |
| 16 Jan 2026 | +107.6% |
| 13 Feb 2026 | +77.5% |
| 20 Feb 2026 | +20.7% |
| 27 Feb 2026 | +19.1% |
| 6 Mar 2026 | +16.6% |
| 13 Mar 2026 | +26.2% |
| 20 Mar 2026 | +16.3% |
| 27 Mar 2026 | +10.6% |
| 2 Apr 2026 | +20.7% |
| 10 Apr 2026 | +15.1% |
| 17 Apr 2026 | +6.9% |
| 24 Apr 2026 | +23.9% |
| 30 Apr 2026 | +6.1% |
| 8 May 2026 | +2.1% |
| 15 May 2026 | +16.6% |
| 22 May 2026 | +58.3% |
| 29 May 2026 | +43.8% |
| 4 Jun 2026 | +66.1% |
| 5 Jun 2026 | +63.9% |
| 9 Jun 2026 | +67.9% |
| 10 Jun 2026 | +55.5% |
| 12 Jun 2026 | +43.0% |
| 17 Jun 2026 | +44.6% |
| 19 Jun 2026 | +26.0% |
| 24 Jun 2026 | +1.2% |
| 25 Jun 2026 | +15.9% |
| 1 Jul 2026 | +21.3% |
| 3 Jul 2026 | +25.4% |
| 10 Jul 2026 | +2.1% |
| 17 Jul 2026 | +2.9% |
| 24 Jul 2026 | −7.3% |
| 31 Jul 2026 | −15.6% |
| 7 Aug 2026 | −17.4% |
| 14 Aug 2026 | −7.5% |
| 21 Aug 2026 | −15.5% |
| 28 Aug 2026 | −14.8% |
| 4 Sep 2026 | −7.5% |
| 11 Sep 2026 | −7.3% |
| 18 Sep 2026 | −6.2% |
| 25 Sep 2026 | +1.3% |
| 1 Oct 2026 | −3.8% |
| 9 Oct 2026 | −3.3% |
| 16 Oct 2026 | −0.2% |
| 23 Oct 2026 | −5.2% |
| 30 Oct 2026 | −3.3% |
| 6 Nov 2026 | −5.1% |
| 8 Nov 2026 | −9.5% |
| 13 Nov 2026 | +0.4% |
| 18 Nov 2026 | −0.5% |
Over the last 1 year the share price moved +211% while the NIFTY 500 moved +4%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 13 November 2026. The chart above shows the 13-week comparison for every week.
This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.
What are Anondita Medicare's latest quarterly results?
For January to March 2026 (the quarter ended 31 March 2026), Anondita Medicare reported revenue of ₹83.0 crore, up 80.4% from ₹46.0 crore a year earlier, and a profit of ₹21.0 crore, up 110.0% from ₹10.0 crore.
Anondita Medicare results: January to March 2026 against a year earlier
| Measure | January to March 2026 | January to March 2025 | Change |
|---|---|---|---|
| Revenue | ₹83.0 crore | ₹46.0 crore | +80.4% |
| Profit | ₹21.0 crore | ₹10.0 crore | +110.0% |
| Earnings per share | ₹10.41 | ₹7.60 | +37.0% |
| Operating margin | 37.3% | 34.8% | +2.5 points |
The next results, for April to June 2026, were due by 14 August 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). This page shows them once our weekly data update has read them.
The newest call in our records is from 16 November 2026, about July to September 2026; a call about these results is not in our records yet.
From the company's reported quarterly results (quarter ended 31 March 2026). Revenue and profit in ₹ crore.
What is the Anondita Medicare share price history?
Anondita Medicare closed at ₹1,059.30 on 18 November 2026, up 70.4% from ₹621.80 a year earlier (21 November 2025). Its highest weekly close since September 2025 was ₹1,233.15 on 24 June 2026.
Anondita Medicare share price: then and now
| When | Close | Change to 18 Nov 2026 |
|---|---|---|
| 1 week ago · 11 Nov 2026 | ₹1,056.60 | +0.3% |
| 1 month ago · 19 Oct 2026 | ₹1,007.45 | +5.1% |
| 6 months ago · 15 May 2026 | ₹929.65 | +13.9% |
| 1 year ago · 21 Nov 2025 | ₹621.80 | +70.4% |
| Earliest and lowest weekly close in our records · 5 Sep 2025 | ₹340.80 | +210.8% |
| Highest weekly close since September 2025, also the 52-week high · 24 Jun 2026 | ₹1,233.15 | −14.1% |
| 52-week low (weekly close) · 25 Nov 2025 | ₹606.43 | +74.7% |
Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.
68 weekly closes from 5 September 2025 to 18 November 2026.
What is the latest news on Anondita Medicare?
18 Nov 2026: Anondita Medicare closed at ₹1,059.30, up 0.3% on the week and up 5.1% on the month. 16 Nov 2026: Anondita Medicare held its results call for July to September 2026. Management guided: FY27 revenue ₹240 crore to ₹250 crore.
Earlier
- Results for January to March 2026: Revenue up 80.4% and profit up 110.0% on a year earlier.
What dividend does Anondita Medicare pay?
Anondita Medicare has paid no dividend on the exchange since its first close in our records (5 September 2025), the start of the period we checked.
No. Anondita Medicare Ltd paid out 0% of its profit as dividends in each of its last 2 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.
From the exchange corporate-actions record, read 18 November 2026.
What did Anondita Medicare management say on the latest results call?
On the call for July to September 2026, held on 16 November 2026, Anondita Medicare's management guided: FY27 revenue ₹240 crore to ₹250 crore.
“We would proudly say that we are the only company in the world that manufactures male latex, male non-latex, female latex, and female non-latex condoms.”Anupam Ghosh, on the call for July to September 2026
What management guided
- FY29 revenue ₹1,000 crore.
- Male annual capacity 1.1 billion pieces by month-end with 4 lines commercial within 2 weeks.
- Female latex 60M capacity across 2 lines ready by December, trials complete finishing underway.
- Female non-latex 2 lines about 120M each to commercial production within FY27, trials starting by December.
Management’s own plans and goals, from our notes of the call. A plan is not a result.
Source: the call transcript.
From the call for July to September 2026, 16 November 2026.
What to watch in Anondita Medicare's next results?
When Anondita Medicare reports April to June 2026, these are the 2 checks that show whether the story is still on course. First: H2 conversion of in-hand domestic, South Africa and own-brand orders with monthly shipments already started.
Management raised each of these on the latest results call.
- H2 conversion of in-hand domestic, South Africa and own-brand orders with monthly shipments already started.
- Male scale-up commissioning and female latex and non-latex trial-to-commercial milestones against guided timelines.
Which stock lists is Anondita Medicare on?
Anondita Medicare is not on any of our India lists this week.
Is Anondita Medicare profitable?
Anondita Medicare Ltd earned ₹21.0 Cr of net profit in the Mar 2026 quarter, +110.0% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹34.0 Cr. The Mar 2026 quarter's profit is 25.3% of that quarter's revenue.
Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.
For the full year, FY26 profit was ₹34.0 Cr (+112.5% on the year before).
How much revenue does Anondita Medicare make, and is it growing?
Anondita Medicare Ltd reported ₹83.0 Cr of revenue in the Mar 2026 quarter, +80.4% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. The last full year, FY26, came in at ₹137 Cr.
Revenue is everything the company billed its customers in the period.
A growth rate over several years is not shown, because there are too few years of figures to work one out properly.
FY26 revenue was ₹137 Cr, +77.9% on the year before.
How much of every ₹100 of sales does Anondita Medicare keep?
Anondita Medicare Ltd's operating margin was 37.3% in the Mar 2026 quarter, 2.5 percentage points higher than the same quarter a year ago.
Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.
Across 2 years it has been between 33.8% and 37.2%.
Why: the operating margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason.
Is Anondita Medicare's profit turning into cash?
Over the last 2 years, 8% of Anondita Medicare Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹11.0 Cr of operating cash against ₹34.0 Cr of profit. After ₹63.0 Cr of spending on assets, free cash was −₹52.0 Cr: it spent more than its operations brought in.
The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.
Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.
Why 8% of profit came in as cash: the cash cycle stayed about the same between FY25 and FY26, so the cash follows profit, not the cycle. When less than 70% of profit comes in as cash, it is the thing to watch on this page.
What to look at next: the bigger use of cash is spending on new assets, at 37.0× depreciation over three years. The next section checks what that spending is building.
Where does Anondita Medicare's cash go?
Anondita Medicare Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 214 days in FY26, down from 218 days in FY25. It spent ₹74.0 Cr on assets over the last 3 years. Customers take 138 days to pay, and stock sits for 125 days on average.
Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.
At FY26 sales of ₹137 Cr, each day of that cycle ties up about ₹0.4 Cr, so roughly ₹80.0 Cr is tied up in the business at any time.
FY26: customers took 138 days to pay and stock sat for 125 days, about 4.1 months of sales sitting as stock, for a full cycle of 214 days, shorter than FY25's 218.
The full loop: cash goes out to suppliers and production on day 0. Stock sits for 125 days. Customers pay about 138 days after that. Suppliers are paid at 48 days. Together that makes the 214-day cycle.
Spending on assets: ₹74.0 Cr over the last 3 years, against ₹2.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹42.0 Cr (FY26): assets paid for that are not earning yet.
In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.
What is Anondita Medicare's P/E ratio, and how does it compare with its own history?
Anondita Medicare Ltd's P/E is 60.3×, near the low end of its own history: it has been lower only 35% of the time. Its usual P/E (the middle reading) is 64.0×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.
P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.
In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.
Is the Anondita Medicare business getting better or worse?
Anondita Medicare Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend.
Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.
Why it matters: with too little history, we say so rather than guess a direction.
One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.
The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.
There are fewer than eight usable quarters, so this page does not guess a direction from so little history.
Compound annual growth rate (%)
Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.
| Measure | 1yr | 3yr | 5yr | 10yr |
|---|---|---|---|---|
| Revenue | +77.9% | — | — | — |
| Profit | +112.5% | — | — | — |
| EPS | +55.1% | — | — | — |
| Share price | +61.1% | — | — | — |
How much does Anondita Medicare earn on its capital?
Anondita Medicare Ltd earned a ROCE of 44% in FY26. Its return on capital used (ROIC) is 11.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 24.8% net margin and 0.74× asset turnover (sales divided by assets).
Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.
Why the return is what it is (FY26): a 24.8% net margin × 0.74× asset turnover × 1.43× leverage (assets divided by equity) ≈ 26.2% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.
The key test, return on capital used minus the cost of capital: 23.8% − 12.0% = +11.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.
The 23.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 33.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.
Does Anondita Medicare have too much debt?
Anondita Medicare Ltd had ₹34.0 Cr of borrowings against ₹129 Cr of equity in FY26, so its debt is 0.26× its equity. Its operating profit is 13 times its interest bill. Over 2 years borrowings went from ₹0.0 Cr to ₹34.0 Cr. Over the last 3 of those years it spent ₹74.0 Cr on assets.
Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.
Part of the spending on assets is being paid for with borrowed money.
What is the Anondita Medicare shareholding pattern?
No group of Anondita Medicare Ltd's owners changed its stake by a full percentage point over the last 3 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.
Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.
How far is Anondita Medicare from balance-sheet trouble?
For Anondita Medicare Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.
The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.
How does Anondita Medicare rank in its industry?
59.4 out of 100, rank 2 of 2 in Contraceptives/Protectives, with 28% of the evidence available. It is provisional, so it is ranked below companies with full evidence.
Anondita Medicare Ltd scores 59.4 out of 100 against the 2 companies it is compared with in Contraceptives/Protectives, ranking 2. Some evidence is missing, so the score is pulled toward the middle on purpose.
The four parts add up to the total exactly: 17.6 + 19.3 + 10 + 12.5 = 59.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here.
What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.
Which companies is Anondita Medicare compared with?
Anondita Medicare ranks 2 of 2 Contraceptives/Protectives companies on the 4-Factor Sector Score, with 59.4 out of 100.
- 1Cupid LtdCUPID · leader · Most evidence points up · 80% evidence79.0out of 100
How the score adds up
Growth & earnings 28.0/35 · Revenue 100% · Profit 100% · Operating margin change -5 points · 100% evidenceCapital efficiency 21.0/25 · ROCE 33.9% (year to Mar 2026) · Operating margin 29.3% · 100% evidenceValuation 10.0/20 · P/E 288.3× · PEG — · 0% evidenceRelative strength 20.0/20 · Strength vs its industry (price vs its 52-week average, weekly) 39.4% · Strength vs NIFTY 500 (same reading) 112.7% · 1 year 439.1% · 100% evidence · 12 of 12 weeks aheadExact sum: 28 + 21 + 10 + 20 = 79 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 2Anondita Medicare Ltd this pageANONDITA · quiet · Too little evidence to rank firmly · 28% evidence59.4out of 100
How the score adds up
Growth & earnings 17.6/35 · Revenue — · Profit — · Operating margin change 3 points · 15% evidenceCapital efficiency 19.3/25 · ROCE 43.8% (year to Mar 2026) · Operating margin 37.4% · 71% evidenceValuation 10.0/20 · P/E 60.3× · PEG — · 0% evidenceRelative strength 12.5/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 8.2% · 1 year 70.4% · 25% evidence · 0 of 12 weeks aheadExact sum: 17.6 + 19.3 + 10 + 12.5 = 59.4 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.
Related companies: Contraceptives/Protectives, all 2 compared on one page.
Which companies are close to Anondita Medicare in size?
Anondita Medicare is the 2nd largest of 2 Contraceptives/Protectives companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Cupid. It is the smallest.
Contraceptives/Protectives companies close in size
- Cupid Ltd ₹48,838 crore
- Anondita Medicare Ltd ₹2,018 crore
Companies close in size in other industries
- Max India Ltd(Merged) ₹2,029 crore · Hospitals & Diagnostics
- Geojit Financial Services Ltd ₹2,025 crore · Finance - Capital Markets - Brokers
- Anondita Medicare Ltd ₹2,018 crore
- Paramount Communications Ltd ₹2,012 crore · Cables - Telecom
- Orissa Minerals Development Company Ltd ₹2,008 crore · Mining/Minerals
What else do people ask about Anondita Medicare?
What is Anondita Medicare's share price today?
Anondita Medicare Ltd's share price is ₹1,059.30, +70.4% over the past year. The whole company is worth ₹2,017 Cr on the market.
In the last 52 weeks it traded between ₹606 to ₹1,233; today it is 72% of the way up from the low, 11.1% above its 200-day average (as of 18 November 2026).
What were Anondita Medicare's latest quarterly results?
Anondita Medicare Ltd reported revenue of ₹83.0 Cr and net profit of ₹21.0 Cr for the Mar 2026 quarter. Revenue rose 80.4% and profit rose 110.0% compared with a year earlier. Earnings per share were ₹10.41.
The operating margin was 37.3%, 2.5 percentage points higher than a year earlier (as of 18 November 2026).
What is Anondita Medicare's market cap?
Anondita Medicare Ltd's market capitalisation is ₹2,017 Cr at a share price of ₹1,059.30. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026).
How is Anondita Medicare performing?
Anondita Medicare Ltd's share price has been rising for 58 weeks. In its latest quarter, revenue rose 80.4% and profit rose 110.0% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 1 week running (as of 18 November 2026).
Will Anondita Medicare's share price go up?
This page does not forecast Anondita Medicare Ltd's share price. What it shows instead: the share price is ₹1,059.30, and it has been rising for 58 weeks. Its P/E of 60.3× is higher than 35% of its own last 1 years (as of 18 November 2026).
Who owns Anondita Medicare?
Promoters own 59.3% of Anondita Medicare Ltd, foreign institutions 2.6%, domestic institutions 6.1% and the public 32.1% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 18 November 2026).
Where is Anondita Medicare in its business cycle?
Anondita Medicare Ltd's FY26 operating margin was 37.2%, against a 2-year range of 33.8% to 37.2%. The latest quarter was 37.3%, above the top of its own yearly range in the latest quarter, so margins are at a high and the story depends on them staying there.
Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026).
What could break the Anondita Medicare story?
The main question: profits are rising, but only 8% of the last 2 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch.
On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026).
Is Anondita Medicare a stock worth studying right now?
What the numbers show: Anondita Medicare Ltd's multiple is near its low because earnings grew even faster than a big multi-year rise in the share price. The multiple is low because of growth, not neglect.
Results are still improving, and its P/E is higher than only 35% of its own 1-year history. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026).
Is there a Anondita Medicare share price forecast for 2026?
What management itself guided: FY27 revenue ₹240 crore to ₹250 crore.
Where do these numbers come from?
Sector Alpha, written by code from the published numbers. Data as of 18 November 2026.
Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.
See the plain-text version of this page.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.